Soleno Therapeutics (NASDAQ: SLNO) and Cardiovascular Systems (NASDAQ:CSII) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.
This table compares Soleno Therapeutics and Cardiovascular Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Soleno Therapeutics and Cardiovascular Systems’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Soleno Therapeutics||$1.45 million||25.08||-$12.06 million||($1.60)||-1.18|
|Cardiovascular Systems||$204.91 million||4.31||-$1.79 million||($0.10)||-266.00|
Cardiovascular Systems has higher revenue and earnings than Soleno Therapeutics. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
46.6% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 82.6% of Cardiovascular Systems shares are held by institutional investors. 69.8% of Soleno Therapeutics shares are held by insiders. Comparatively, 3.3% of Cardiovascular Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for Soleno Therapeutics and Cardiovascular Systems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soleno Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 111.64%. Cardiovascular Systems has a consensus price target of $26.50, indicating a potential downside of 0.38%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Soleno Therapeutics is more favorable than Cardiovascular Systems.
Volatility and Risk
Soleno Therapeutics has a beta of 5.27, indicating that its share price is 427% more volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500.
Cardiovascular Systems beats Soleno Therapeutics on 7 of the 13 factors compared between the two stocks.
About Soleno Therapeutics
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
About Cardiovascular Systems
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.